Alpha Centric Advisors LLC Amylyx Pharmaceuticals, Inc. Transaction History

Alpha Centric Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $66,385 - $101,530	5,500 Added 3.78%	151,000 $2.22 Million
Q3 2023 Nov 13, 2023	BUY	$18.08 - $23.45 $677,999 - $879,375	37,500 Added 34.72%	145,500 $2.66 Million
Q2 2023 Aug 08, 2023	BUY	$20.98 - $31.42 $2.11 Million - $3.16 Million	100,500 Added 1340.0%	108,000 $2.33 Million
Q1 2023 May 12, 2023	BUY	$27.71 - $40.93 $207,825 - $306,975	7,500 New	7,500 $220,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.